Oral News and Research

RSS

Many phase I trials for new cancer fighting drugs never get reported in peer-reviewed journals

A new study finds many phase I trials for new cancer fighting drugs never get reported in peer-reviewed journals, and says investigators should be committed not just to finding novel compounds, but also to make sure final results of their studies be disseminated to the medical community.

22 Aug 2005

Phase I cancer findings under-reported

Phase I cancer studies, trials that are conducted to determine the safety and maximum dose of a new agent, are under-reported in peer-reviewed journals - a trend that could ultimately delay scientific progress and negatively affect patient care, say researchers at The University of Texas M. D. Anderson Cancer Center in a new study out today (Mon., Aug, 22) online in Cancer.

22 Aug 2005

Women who take oral contraceptives can counteract bone loss by increasing calcium in their daily diet

Women who take oral contraceptives can counteract bone loss by making sure they have enough calcium in their daily diet, especially early in life, according to Purdue University research.

17 Aug 2005

The use of salt fluoridation to prevent dental caries

A new book from the Pan American Health Organization (PAHO) shows how salt fluoridation has proven to be one of the most cost-effective public health interventions in history and shows countries how to implement programs of their own.

16 Aug 2005

Enzyme called matriptase, when left to its own devices, can cause cance

Scientists at the National Institute of Dental and Craniofacial Research (NIDCR) and colleagues report in animal studies that a single, scissor-like enzyme called matriptase, when left to its own devices, can cause cancer.

16 Aug 2005

Oral medications may control symptoms of Type II diabetes in children just as well as insulin injections

According to the medical records of 26 children diagnosed with the disease, oral medications reduced levels of a compound in the blood called hemoglobin A1C by an average of 2 percentage points.

15 Aug 2005

New therapeutic approach that could help eliminate dormant HIV infection

US scientists have tested a new therapeutic approach that could help eliminate dormant HIV infection that current treatments miss. The researchers report these preliminary findings in a proof-of-concept study in this week’s issue of The Lancet.

11 Aug 2005

FDA approval sought for Pfizer's new cancer drug

Drug company Pfizer has announced it has submitted a New Drug Application (NDA) for its cancer drug Sutent, to the U.S. Food and Drug Administration (FDA).

11 Aug 2005

Expert warns of spread of Rocky Mountain Spotted Fever

An expert on infectious diseases at Johns Hopkins University School of Medicine, is warning that humans can inadvertently help spread infectious organisms beyond traditional state boundaries.

11 Aug 2005

Strawberries most effective at inducing cancer cell death

Strawberries may be the most effective of the five most commonly consumed berries at inducing cancer cell death, according to a recent study conducted at the UCLA Center for Human Nutrition.

10 Aug 2005

Findings do not support the hypothesis of increased risk of nontargeted infectious disease hospitalization after childhood vaccination

New research does not support a belief that children receiving multiple vaccines increase their risk of hospitalization for a nontargeted infectious disease, according to a study in the August 10 issue of JAMA: The Journal of the American Medical Association.

9 Aug 2005

Table salt fluoridation can reduce the prevalence of dental caries

Table salt fluoridation can reduce the prevalence of dental caries up to 84 percent, according to a new book published by the Pan American Health Organization (PAHO), "Promoting Oral Health: The Use of Salt Fluoridation to Prevent Dental Caries".

4 Aug 2005

Breed and placement affect skin drug delivery

Skin creams and patches might be the easiest way to give your pets medicine but their success also depends on the breed and where it’s applied.

2 Aug 2005

MediciNova starts phase II clinical trial of MN-166 for multiple sclerosis

MediciNova today announced the enrollment of patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. MN-166 is an orally administered drug with a novel mechanism of action that includes the inhibition of phosphodiesterase IV.

2 Aug 2005

Inhibitors of cellular enzymes could be developed for SARS treatment

Researchers from the University of Pennsylvania School of Medicine have found that inhibitors of an enzyme called cathepsin L prevent the SARS (severe acute respiratory syndrome) virus from entering target cells. SARS is caused by an emergent coronavirus. There is no effective treatment at this time.

1 Aug 2005

Birth control pill increases risks of cervical and breast cancer

Scientists are now saying that women who take the birth control pill could be increasing their risk of cervical and breast cancer.

31 Jul 2005

Bacteria in the mouth could freshen up bad breath

Researchers in the UK say they have isolated bacteria which can grow on and destroy some of the compounds that cause bad breath, and this discovery could help develop a natural way to beat halitosis and other odours such as smelly feet.

28 Jul 2005

Ranbaxy receives tentative approval to manufacture and market Glimepiride tablets

Indian drug manufacturer, Ranbaxy Pharmaceuticals has tentative approval from the U.S. Food and Drug Administration to manufacture and market Glimepiride Tablets, 3 mg and 6 mg.

28 Jul 2005

Loyola researchers hope that zoledronic acid will be effective and safe for patients with inflammatory bowel diseases (IBD)

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

26 Jul 2005

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

26 Jul 2005